GKOS Stock Analysis: Glaukos | NYSE
Medical Devices | NYSE, USA | Market Cap: 8.967m USD | 12M Return: 43.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 123M
Qual. Beats: 0
Rev. Trend: 98.8%
Qual. Beats: 8
Warnings
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Glaukos Corporation (NYSE: GKOS) is an ophthalmic pharmaceutical and medical technology company headquartered in Aliso Viejo, California, and incorporated in 1998. The company develops therapies targeting glaucoma, corneal disorders, and retinal diseases, with operations spanning the United States and international markets.
Its core glaucoma portfolio includes the iStent and iStent inject W micro-bypass stents, the iStent infinite for refractory cases, and iDose TR, an intracameral procedural pharmaceutical therapy designed to lower intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The pipeline also extends to corneal health through iLink for keratoconus treatment, ILution for transdermal anterior segment drug delivery, and a retinal XR platform addressing age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment conditions.
Products are sold through a direct sales organization, subsidiaries, and distributors to ambulatory surgery centers, hospitals, and physician private practices. As a mid-cap healthcare equipment company within the medical devices subsector, Glaukos operates at the intersection of interventional ophthalmology and sustained-release pharmaceutical delivery, a hybrid model that distinguishes it from purely device-based peers and from traditional topical glaucoma drug manufacturers.
- iDose TR commercial uptake drives glaucoma franchise growth
- Retinal pipeline progress targets AMD and DME markets
- iStent faces intensified MIGS competition from surgical rivals
| Net Income: -189.3m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.02 > 0.02 and ΔFCF/TA 3.44 > 1.0 |
| NWC/Revenue: 71.89% < 20% (prev 92.95%; Δ -21.07% < -1%) |
| CFO/TA -0.01 > 3% & CFO -8.79m > Net Income -189.3m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 5.43 > 1.5 & < 3 |
| Outstanding Shares: last quarter (58.0m) vs 12m ago 2.45% < -2% |
| Gross Margin: 78.08% > 18% (prev 75.75%; Δ 2.33% > 0.5%) |
| Asset Turnover: 59.30% > 50% (prev 41.87%; Δ 17.43% > 0%) |
| Interest Coverage Ratio: -41.31 > 6 (EBIT TTM -189.9m / Interest Expense TTM 4.60m) |
| A: 0.44 (Total Current Assets 485.8m - Total Current Liabilities 89.4m) / Total Assets 893.3m |
| B: -1.07 (Retained Earnings -952.9m / Total Assets 893.3m) |
| C: -0.20 (EBIT TTM -189.9m / Avg Total Assets 929.8m) |
| D: 3.02 (Book Value of Equity 670.9m / Total Liabilities 222.4m) |
| Altman-Z'' = 1.23 = BB |
| DSRI: 1.23 (Receivables 119.7m/71.5m, Revenue 551.3m/404.5m) |
| GMI: 0.97 (GM 75.75% / 78.08%) |
| AQI: 0.69 (AQ_t 0.25 / AQ_t-1 0.36) |
| SGI: 1.36 (Revenue 551.3m / 404.5m) |
| TATA: -0.20 (NI -189.3m - CFO -8.79m) / TA 893.3m) |
| Beneish M = -2.81 (Cap -4..+1) = A |
As of July 11, 2026, the stock is trading at USD 152.72 with a total of 672,304 shares traded. Over the past week, the price has changed by +2.95%, over one month by +24.68%, over three months by +31.20% and over the past year by +43.33%.
Current recommended Stop Loss: 141.80 (which is 7.2% or 1.8 ATR below the current price).
Glaukos has received a consensus analysts rating of 4.27. Therefore, it is recommended to buy GKOS.
- StrongBuy: 9
- Buy: 3
- Hold: 2
- Sell: 0
- StrongSell: 1
| Analysts Target Price | 158.3 | 3.7% |
P/E Forward = 2000.0
P/S = 16.2646
P/B = 12.9859
P/EG = 1.64
Revenue TTM = 551.3m USD
EBIT TTM = -189.9m USD
EBITDA TTM = -144.0m USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = 103.1m USD (from shortLongTermDebtTotal, last quarter) (leases 103.1m already included)
Net Debt = -173.6m USD (calculated: Debt 103.1m - CCE 276.7m)
Enterprise Value = 8.79b USD (8.97b + Debt 103.1m - CCE 276.7m)
Interest Coverage Ratio = -41.31 (Ebit TTM -189.9m / Interest Expense TTM 4.60m)
EV/FCF = -475.8x (Enterprise Value 8.79b / FCF TTM -18.5m)
FCF Yield = -0.21% (FCF TTM -18.5m / Enterprise Value 8.79b)
FCF Margin = -3.35% (FCF TTM -18.5m / Revenue TTM 551.3m)
Net Margin = -34.34% (Net Income TTM -189.3m / Revenue TTM 551.3m)
Gross Margin = 78.08% ((Revenue TTM 551.3m - Cost of Revenue TTM 120.8m) / Revenue TTM)
Gross Margin QoQ = 77.86% (prev 77.80%)
Tobins Q-Ratio = 9.84 (Enterprise Value 8.79b / Total Assets 893.3m)
Interest Expense / Debt = 4.46% (Interest Expense 4.60m / Debt 103.1m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -150.0m (EBIT -189.9m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 5.43 (Total Current Assets 485.8m / Total Current Liabilities 89.4m)
Debt / Equity = 0.15 (Debt 103.1m / totalStockholderEquity, last quarter 670.9m)
Debt / EBITDA = 1.21 (negative EBITDA) (Net Debt -173.6m / EBITDA -144.0m)
Debt / FCF = 9.40 (negative FCF - burning cash) (Net Debt -173.6m / FCF TTM -18.5m)
Total Stockholder Equity = 715.4m (last 4 quarters mean from totalStockholderEquity)
RoA = -20.36% (Net Income -189.3m / Total Assets 893.3m)
RoE = -26.46% (Net Income TTM -189.3m / Total Stockholder Equity 715.4m)
RoCE = -23.63% (EBIT -189.9m / Capital Employed (Total Assets 893.3m - Current Liab 89.4m))
RoIC = -19.33% (negative operating profit) (NOPAT -150.0m / Invested Capital 776.3m)
WACC = 8.78% (E(8.97b)/V(9.07b) * Re(8.84%) + D(103.1m)/V(9.07b) * Rd(4.46%) * (1-Tc(0.21)))
Discount Rate = 8.84% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 7.92%
[DCF] Fair Price = unknown (Cash Flow -18.5m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.36 | # QB: 0
Revenue Correlation: 98.78 | Revenue CAGR: 25.47% | SUE: 4.0 | # QB: 8
EPS current Quarter (2026-06-30): EPS=-0.21 | Chg30d=-0.38% | Revisions=-40% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-0.13 | Chg30d=+0.00% | Revisions=+0% | Analysts=13
EPS current Year (2026-12-31): EPS=-0.51 | Chg30d=+0.00% | Revisions=+40% | GrowthEPS=+42.9% | GrowthRev=+24.2%
EPS next Year (2027-12-31): EPS=0.44 | Chg30d=-7.74% | Revisions=+17% | GrowthEPS=+186.3% | GrowthRev=+25.8%
[Analyst] Revisions Ratio: +10% (up=4, down=3)